HDAC10
HDAC10 (histone deacetylase 10) is a zinc-dependent class IIb histone deacetylase that functions primarily as a polyamine deacetylase, representing a distinct enzymatic activity within the HDAC family[1]. Mechanistically, HDAC10 regulates polyamine metabolism and contributes to cellular homeostasis through pathways linked to autophagy and lysosomal function, making it an important epigenetic regulator beyond canonical histone deacetylation[1][2]. In disease-related studies, HDAC10 has attracted considerable interest in cancer biology, where altered HDAC10 activity has been associated with tumor-relevant cellular processes and therapeutic response mechanisms[2][3]. Experimental evidence further indicates that pharmacological or genetic inhibition of HDAC10 can promote autolysosome accumulation in neuroblastoma models, supporting a functional connection between HDAC10 and autophagy regulation[3][4]. Compared with its closest class IIb homolog HDAC6, HDAC10 exhibits unique substrate selectivity and is currently recognized as the only identified HDAC family member with established polyamine deacetylase activity, highlighting a major functional distinction between these related isoforms[1][2]. Structural studies have identified characteristic features, including the acidic gatekeeper residue Glu274, that contribute to substrate recognition and isoform selectivity[4]. For experimental applications, the development of selective HDAC10 inhibitors has enabled more precise interrogation of HDAC10-dependent biology, and recent compounds have demonstrated high selectivity over HDAC6 while serving as valuable chemical probes for investigating autophagy, cancer-associated pathways, and polyamine-dependent cellular processes[1][4].
References:
- [1]. Lambona C, et al. Histone deacetylase 10: A polyamine deacetylase from the crystal structure to the first inhibitors. Curr Opin Struct Biol. 2023 Oct;82:102668. [Content Brief]
- [2]. Delcuve GP, et al. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012 Mar 12;4(1):5. [Content Brief]
- [3]. Tarawneh AH, et al. Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics. Sci Rep. 2025;15:33307.
- [4]. Zeyen P, et al. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. Eur J Med Chem. 2022 Apr 15;234:114272. doi: 10.1016/j.ejmech.2022.114272. Epub 2022 Mar 11. PMID: 35306288; PMCID: PMC9007901. [Content Brief]
-
HDAC10 Related Products (67)
Related Products (67)
-
Antibodies (1)
-
ZG-126
0 ImagesCat. No.: HY-161778CAS No.: 3049802-32-3ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization.
-
Quisinostat hydrochloride
0 ImagesCat. No.: HY-15433BCAS No.: 1083078-98-1Synonyms: JNJ26481585 hydrochlorideQuisinostat (JNJ-26481585) hydrochloride is a potent and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat hydrochloride has a broad spectrum antitumoral activity. Quisinostat hydrochloride can induce autophagy in neuroblastoma cells.
-
YDH-704
0 ImagesCat. No.: HY-187370YDH-704 is a PAK1/HDAC10 inhibitor, with IC50 values of 0.05 μM and 0.02 μM against human targets, respectively. YDH-704 blocks PAK1-mediated oncogenic signaling pathways, inhibits the proliferation and migration of tumor cells, suppresses the epigenetic regulatory function of HDAC10, downregulates PD-L1 expression, and regulates polyamine metabolism. YDH-704 reduces MDSC/Treg infiltration, enhances the infiltration and activation of CD8+ T cells, and inhibits tumor growth and lung metastasis. YDH-704 can be used for research on triple-negative breast cancer.
-
CM-444
0 ImagesCat. No.: HY-163803CAS No.: 2256079-52-2CM-444 is inhibitor for HDAC (IC50 is 6 nM-0.6 μM) and DNA methyltransferases (DNMT, IC50 is 1.8-2.3 μM). CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models.
-
HDAC6-IN-74
0 ImagesCat. No.: HY-181579HDAC6-IN-74 is an orally active, selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.036 μM. HDAC6-IN-74 induces tumor cell apoptosis, arrests cells at the S phase of the cell cycle, and impairs cell migration, invasion and colony-forming abilities. HDAC6-IN-74 exerts anticancer effects with no obvious toxicity. HDAC6-IN-74 can be used in the research of cancers such as liver cancer.
-
CRA-026440
0 ImagesCat. No.: HY-19754CAS No.: 847460-34-8CRA-026440 is a potent, broad-spectrum HDAC inhibitor. The Ki values against recombinant HDAC isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are 4, 14, 11, 15, 7, and 20 nM respectively. CRA-026440 shows antitumor and antiangiogenic activities. CRA-026440 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
